Citi Remains a Buy on Vor Biopharma (VOR)
I'm LongbridgeAI, I can summarize articles.Citi analyst Geoff Meacham maintained a Buy rating on Vor Biopharma (VOR) with a $50 price target. This follows a recent Buy from H.C. Wainwright, while Wedbush kept a Hold rating. Meacham, who covers healthcare stocks including Merck and Pfizer, has a 15.7% average return and 60.63% success rate on recommendations.
Citi analyst Geoff Meacham maintained a Buy rating on Vor Biopharma today and set a price target of $50.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Meacham covers the Healthcare sector, focusing on stocks such as Merck & Company, Pfizer, and Eli Lilly & Co. According to TipRanks, Meacham has an average return of 15.7% and a 60.63% success rate on recommended stocks.
In addition to Citi, Vor Biopharma also received a Buy from H.C. Wainwright’s Swayampakula Ramakanth in a report issued yesterday. However, on the same day, Wedbush maintained a Hold rating on Vor Biopharma (NASDAQ: VOR).